Cancer Cell



Zetagen is committed to the treatment of metastatic cancer lesions. Bone metastases are common among cancer patients and occur when cells from the primary cancerous tumor relocate to the bone. When these cancers relocate, they can cause changes to the bone, damaging it in a process called osteolysis. Osteolysis can cause small holes within the bone, weakening it and increasing the risk of breakage. These holes are called “lytic lesions.” Among cancers which metastasize to bone, Breast and Prostate are most prevalent, amounting to approximately 70-percent of cases.[1]
Lytic lesions can cause severe, debilitating pain in patients with advanced cancer. Patients with these lesions often experience a reduced quality of life with multiple skeletal-related events (SREs), including fractures, spinal cord compression, elevated levels of calcium in the blood or “hypercalcaemia”, bone marrow infiltration and severe bone pain.[2] Bone metastases are also a major cause for morbidity in patients with advanced stage cancer.[3]

Our product, ZetaMet™ has thus far demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain, and stimulate targeted bone regeneration.
[1] Li S, Peng Y, Weinhandl ED, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012;4:87-93. doi:10.2147/CLEP.S28339
[2] Ibrahim T, Mercatali L, Amadori D. A new emergency in oncology: Bone metastases in breast cancer patients (Review). Oncol Lett. 2013;6(2):306-310. doi:10.3892/ol.2013.1372
[3] Cecchini M, Wetterwald A, Pluijm G, Thalmann G. Molecular and biological mechanisms of bone metastasis. EAU Update Series 2005;3:214-26. [Google Scholar]


ZetaMet™ is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone. The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971. Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic conditions.

ZetaMet Settable™

ZetaMet Settable™ is being designed for the treatment of patients with metastatic lesions that have or will result in a Skeletal-Related Event, (SRE) including fractures and spinal cord compression.

A vertebroplasty procedure is a way to treat vertebral body compression fractures, which are small breaks in the thick mass of bone that make up the front part of the spinal column “the vertebral body”. Vertebral body fractures lead to the collapse or compression of a vertebrae, causing the spine to shorten and curve forward, and result in pain and kyphosis (hunched over deformity). Thinning of bone, or osteoporosis is the main cause of vertebral compression fractures. Pathologic fractures relating to spinal tumors may also be a cause.

ZetaMet Settable™ will be administered via a minimally invasive percutaneous vertebroplasty outpatient procedure.